Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy.

ABSTRACT:

Aims

Pathological cardiac remodelling and subsequent heart failure represents an unmet clinical need. Long non-coding RNAs (lncRNAs) are emerging as crucial molecular orchestrators of disease processes, including that of heart diseases. Here, we report on the powerful therapeutic potential of the conserved lncRNA H19 in the treatment of pathological cardiac hypertrophy.

Method and results

Pressure overload-induced left ventricular cardiac remodelling revealed an up-regulation of H19 in the early phase but strong sustained repression upon reaching the decompensated phase of heart failure. The translational potential of H19 is highlighted by its repression in a large animal (pig) model of left ventricular hypertrophy, in diseased human heart samples, in human stem cell-derived

SUBMITTER: Viereck J 

PROVIDER: S-EPMC8482849 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature